By a News Reporter-Staff News Editor at Biotech Week -- Investigators discuss new findings in Oncology. According to news reporting from Cleveland, Ohio, by NewsRx journalists, research stated, "Gene markers or biomarkers can be used for diagnostic or prognostic purposes for all different types of complex disease, including brain tumors. Prognostic markers can be useful to explain differences not only in overall survival but also in response to treatment and for development of targeted therapies."
The news correspondents obtained a quote from the research from University Hospital, "Multiple genes with specific types of alterations have now been identified that are associated with improved response to chemotherapy and radiotherapy, such as O-6-methylguanine methyltranferase (MGMT) or loss of chromosomes 1p and/or 19q. Other alterations have been identified that are associated with improved overall survival, such as mutations in isocitrate dehydrogenase 1 (IDH1) and/or isocitrate dehydrogenase 2 (IDH2) or having the glioma CpG island DNA methylator phenotype (G-CIMP). There are many biomarkers that may have relevance in brain tumor-associated epilepsy that do not respond to treatment. Given the rapidly changing landscape of high throughput omics technologies, there is significant potential for gaining further knowledge via integration of multiple different types of high genome-wide data."
According to the news reporters, the research concluded: "This knowledge can be translated into improved therapies and clinical outcomes for patients with brain tumors."
For more information on this research see: Gene markers in brain tumors: What the epileptologist should know. Epilepsia, 2013;54():25-29. Epilepsia can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Epilepsia - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1528-1167)
Our news journalists report that additional information may be obtained by contacting Q. Ostrom, Case Western Reserve Sch Med, Univ Hosp Case Med Center, Dept. of Neurosurg, Brain Tumor & Neurooncol Center, Cleveland, OH, United States. Additional authors for this research include M.L. Cohen, A. Ondracek, A. Sloan and J. Barnholtz-Sloan (see also Oncology).
Keywords for this news article include: Ohio, Drugs, Genetics, Oncology, Cleveland, Treatment, Brain Cancer, Chemotherapy, Radiotherapy, United States, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC